Study the alternative immunological parameters of immune cells (sCD14 and sCD163) in patients with chronic viral hepatitis B and C without treatment

Zahraa Al-Tamimi; Alia E. M. Alubadi; Luma G. Alsaadi

doi:10.47419/bjbabs.v5i3.298

Authors

Zahraa Al-Tamimi Department of Biology, College of Science, Mustansiriyah University,Baghdad ,Iraq. https://orcid.org/0009-0003-1420-790X
Alia E. M. Alubadi Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0001-9580-9192
Luma G. Alsaadi Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0003-4462-108X

DOI:

https://doi.org/10.47419/bjbabs.v5i3.298

Keywords:

HBV, sCD14, sCD163

Abstract

Soluble Cluster of Differentiation 14 (sCD14) and soluble Cluster of Differentiation 163 (sCD163) are the circulating forms of the cell surface receptors CD14 and CD163 expressed on the surface of monocytes and macrophages. When these cells become activated, the extracellular domains of the CD14 and CD163 receptors are shed or cleaved from the cell surface, releasing the soluble forms in the circulation, which are considered valuable biomarkers for evaluating inflammatory conditions. The sCD14 and sCD163 were both done using the ELISA technique, which showed a significant difference between the patient and control groups. Where these parameters increased in the patient groups compared to the control group, sCD14(ng/ml) was in the HBV group (44.2±7.9), the HCV group (46.8±8.9), and the healthy group (35.1 ± 6.5), while sCD163(ng/ml) was in the HBV group (106.8±9.4), the HCV group (104.3±3.3), and the healthy group (93.01±5.9). The P value was < 0.000 for both parameters. Receiver Operating Characteristic (ROC) analysis shows that it can distinguish patients from controls. It was performed by using the serum levels of each sCD14 and sCD163 in patients with HBV and HCV and a healthy control group according to the presence of the disease. The diagnostic performance of these soluble biomarkers was evaluated in the two patient groups (HBV and HCV) by using ROC analysis, and sCD163 showed a higher diagnostic performance compared to sCD14, where was the area under the curve in the HBV group 0.96 vs. 0.83 while in HCV group 0.97 vs. 0.86 respectively, with statistically significant differences (P = 0.000). In conclusion, the results of this study demonstrate that sCD163 is a more useful and reliable biomarker for predicting and differentiating HBV and HCV infection compared to sCD14, and sCD163 could be a valuable non-invasive tool for the clinical management of viral hepatitis. infection compared to sCD14, and sCD163 could be a valuable non-invasive tool for the clinical management of viral hepatitis.

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

References

Ringehan M, Mckeating JA, Protzer U. Viral hepatitis and liver cancer. Philosophical Transactions of the Royal Society B: Biological Sciences. 2017;1732(372). DOI: 10.1098/rstb.2016.0274

Saeed NAAA, Hamzah IH, Al-Kadmy IM. Prevalence study of different methods for hepatitis B virus diagnosis with blood donor people in Baghdad city. Reviews and Research in Medical Microbiology. 2022;33(3):160–167. DOI: 10.1097/MRM.0000000000000277

Streicher F, Jouvenet N. Stimulation of innate immunity by host and viral RNAs. Trends in Immunology. 2019;40(12):1134–1148. DOI: 10.1016/j.it.2019.10.009.

Xu C, Chen J, Chen X. Host innate immunity against hepatitis viruses and viral immune evasion. Frontiers in Microbiology. 2021;12:740464–740464. DOI: 10.3389/fmicb.2021.740464

Al-Dabagh MA. Evaluation of Immune Response in Patients with Chronic Hep- atitis B Infection. II: Humoral Immunity. Al-Mustansiriyah Journal of Science. 2011;22(5):1–11.

Al-Jaryan EA, Alsaadi LG, Alubadi AE, Magtooph MG. Pivotal Role of Serum IL- 37 In Patients with Chronic HBV and HCV. Al-Mustansiriyah Journal of Science. 2023;34(3):15–23. DOI: 10.23851/mjs.v34i3.1346

Al-Tamimi AAA. Effect of Hepatitis C Virus Infection on Lymphocytes Proliferation. Al-Mustansiriyah Journal of Science. 2011;22(4):1-13.

Luo Q, Xiao P, Li X, Deng Z, Qing C, Su R, et al. Overexpression of CD64 on CD14++ CD16 and CD14++ CD16+ monocytes of rheumatoid arthritis patients correlates with disease activity. Experimental and therapeutic medicine.2018;16(3):2703-2711. DOI:10.3892/etm.2018.6452

Ma S, Murakami K, Saito R, Ito H, Murata K, Nishitani K, et al. Increased Ratio of CD14++ CD80+ Cells/CD14++ CD163+ Cells in the Infrapatellar Fat Pad of End- Stage Arthropathy Patients. Frontiers in Immunology. 2021;12:774177–774177. DOI: 10.3389/fimmu.2021.774177

Yap YJ, Wong PF, Abubakar S, Sam SS, Shunmugarajoo A, Soh YH, et al. The clinical utility of CD163 in viral diseases. Clinica Chimica Acta. 2023;541:117243. DOI: 10.1016/j.cca.2023.117243. DOI: 10.1016/j.cca.2023.117243

Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS. 2015;29(10):1263–1265. DOI: 10.1097/QAD.0000000000000735

Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccala P, Perri V, et al. Increased sCD163 and sCD14 plasmatic levels and depletion of peripheral blood pro- inflammatory monocytes, myeloid and plasmacytoid dendritic cells in patients with severe COVID-19 pneumonia. Frontiers in immunology. 2021;12:627548–627548. DOI: 10.3389/fimmu.2021.627548

Mascia C, Pozzetto I, Kertusha B, Marocco R, Borgo CD, Tieghi T, et al. Persistent high plasma levels of sCD163 and sCD14 in adult patients with measles virus infec- tion. PLoS One. 2018;13(5):e0198174. DOI: 10.1371/journal.pone.0198174

Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I, Gómez-Carballa A, Cebey-López M, Rodríguez-Tenreiro C, et al. Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology. Frontiers in Immunology. 2020;11:560381–560381. DOI: 10.3389/fimmu.2020.560381.

Li L, Cai W, Guo P, Hu F, Lan Y, Li Y, et al. Characteristics and clinical significance of plasma IL-18, sCD14, and sCD163 levels in patients with HIV-1 infection. Journal of Medical Virology. 2023;95(1) e28223. DOI: 10.1002/jmv.28223

Kazankov K, Barrera F, Møller HJ, Bibby BM, Vilstrup H, George J, et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014;60(2):521–530. DOI: 10.1002/hep.27129. 10.1002/hep.27129

Medhat E, Salama H, Fouad H, Haleem HAE, Said M, El-Nahaas SM, et al. Serum soluble CD14 in Egyptian patients with chronic hepatitis C: its relationship to disease progression and response to treatment. Journal of Interferon & Cytokine Research. 2015;35(7):563–568. DOI: 10.1089/jir.2014.0155

Li N, Zhu Q, Yang C, Li F, Zhou Z, Lv Y, et al. Elevated serum soluble CD14 levels in chronic HBV infection are significantly associated with HBV-related hepatocellular carcinoma. Tumor Biology. 2016;37(5):6607–6617. DOI: 10.1007/s13277-015-4423-x

Parfieniuk-Kowerda A, Grubczak K, Eljaszewicz A, Świderska M, Maciaszek M, Panasiuk A, et al. High CD163 expression on classical monocytes is associated with immune control of HBV infection in noncirrhotic patients. Mediators of Inflamma- tion. 2020;2020:1–13. DOI: 10.1155/2020/6364258

Cairoli V, Matteo ED, Casciato P, Ameigeiras B, Preciado MV, Valva P. The perfor- mance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. Plos one. 2022;17(7): e0270911. DOI: 10.1371/journal.pone.0270911

Vidal K, Labéta MO, Schiffrin EJ, Donnet-Hughes A. Soluble CD14 in human breast milk and its role in innate immune responses. Acta Odontologica Scandinavica. 2001;59(5):330–334. DOI: 10.1080/000163501750541219

Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, et al. Macrophage activation markers, soluble CD163 and mannose receptor, in liver fibro- sis. Frontiers in Medicine. 2021;7:615599–615599. DOI: 10.3389/fmed.2020.615599

Xie P, Yao B, Huang D, Chen Y, Gong Q, Zhang X. Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss. Journal of Clinical and Translational Hepatology. 2022;10(6): 1059-1067. DOI: 10.14218/JCTH.2021.00496

Na K, Oh BC, Jung Y. Multifaceted role of CD14 in innate immunity and tissue homeostasis. Cytokine & Growth Factor Reviews. 2023;74:100-107. DOI: 10.1016/j.cytogfr.2023.08.008.